Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

  • 1.

    National Cancer Institute. SEER cancer statistics review 1975-2013: myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML). 2016. Available at: http://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01.html. Accessed November 8, 2016.

    • Search Google Scholar
    • Export Citation
  • 2.

    Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:15361542.

  • 3.

    Greenberg P. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, eds. Hematology: Basic Principles and Practice, 3rd ed. New York, NY: Churchill Livingstone; 2000;11061129.

    • Search Google Scholar
    • Export Citation
  • 4.

    Kaloutsi V, Kohlmeyer U, Maschek H. Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. Am J Clin Pathol 1994;101:123129.

    • Search Google Scholar
    • Export Citation
  • 5.

    Valent P, Horny HP, Bennett JM. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727736.

    • Search Google Scholar
    • Export Citation
  • 6.

    Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016;127:23912405.

    • Search Google Scholar
    • Export Citation
  • 7.

    Greenberg PL, Tuechler H, Schanz J. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood 2016;128:20962097.

    • Search Google Scholar
    • Export Citation
  • 8.

    Brunning R, Bennett J, Flandrin G. Myelodysplastic syndromes. In: Jaffe E, Harris N, Stein H, eds. WHO Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:6173.

    • Search Google Scholar
    • Export Citation
  • 9.

    Harris NL, Jaffe ES, Diebold J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 10.

    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:22922302.

  • 11.

    Brunning R, Orazi A, Germing U. Myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008;87104.

    • Search Google Scholar
    • Export Citation
  • 12.

    Vardiman JW, Thiele J, Arber DA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937951.

    • Search Google Scholar
    • Export Citation
  • 13.

    Schanz J, Tuchler H, Sole F. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820829.

    • Search Google Scholar
    • Export Citation
  • 14.

    Germing U, Lauseker M, Hildebrandt B. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012;26:12861292.

    • Search Google Scholar
    • Export Citation
  • 15.

    Mallo M, Cervera J, Schanz J. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011;25:110120.

    • Search Google Scholar
    • Export Citation
  • 16.

    Arber DA, Brunning RD, Orazi A. Acute myeloid leukaemia with myelodysplastia-related changes. In: Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008:124126.

    • Search Google Scholar
    • Export Citation
  • 17.

    Hasserjian RP, Campigotto F, Klepeis V. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with >/=30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol 2014;89:e193199.

    • Search Google Scholar
    • Export Citation
  • 18.

    Albitar M, Manshouri T, Shen Y. Myelodysplastic syndrome is not merely “preleukemia”. Blood 2002;100:791798.

  • 19.

    Greenberg P, Anderson J, de Witte T. Problematic WHO reclassification of myelodysplastic syndromes. Clin Oncol 2000;18:34473452.

  • 20.

    Germing U, Gattermann N, Strupp C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983992.

    • Search Google Scholar
    • Export Citation
  • 21.

    Germing U, Strupp C, Kuendgen A. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol 2006;132:162167.

    • Search Google Scholar
    • Export Citation
  • 22.

    Germing U, Strupp C, Kuendgen A. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91:15961604.

    • Search Google Scholar
    • Export Citation
  • 23.

    Malcovati L, Porta MG, Pascutto C. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:75947603.

    • Search Google Scholar
    • Export Citation
  • 24.

    Muller-Berndorff H, Haas PS, Kunzmann R. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol 2006;85:502513.

    • Search Google Scholar
    • Export Citation
  • 25.

    Greenberg P, Cox C, LeBeau MM. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood 1998;2091:1100]. Blood 1997;89:20792088.

    • Search Google Scholar
    • Export Citation
  • 26.

    List A, Dewald G, Bennett J. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:14561465.

  • 27.

    Taskesen E, Havermans M, van Lom K. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood 2014;123:33273335.

    • Search Google Scholar
    • Export Citation
  • 28.

    Lindsley RC, Mar BG, Mazzola E. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015;125:13671376.

  • 29.

    Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008.

  • 30.

    Wang SA, Hasserjian RP, Fox PS. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014;123:26452651.

    • Search Google Scholar
    • Export Citation
  • 31.

    Meggendorfer M, Bacher U, Alpermann T. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013;27:18521860.

    • Search Google Scholar
    • Export Citation
  • 32.

    Piazza R, Valletta S, Winkelmann N. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45:1824.

  • 33.

    Gambacorti-Passerini CB, Donadoni C, Parmiani A. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 2015;125:499503.

  • 34.

    Sakaguchi H, Okuno Y, Muramatsu H. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013;45:937941.

    • Search Google Scholar
    • Export Citation
  • 35.

    Vardiman JW, Bennett JM, Bain BJ. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008:8586.

    • Search Google Scholar
    • Export Citation
  • 36.

    Papaemmanuil E, Cazzola M, Boultwood J. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:13841395.

  • 37.

    Malcovati L, Papaemmanuil E, Bowen DT. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118:62396246.

    • Search Google Scholar
    • Export Citation
  • 38.

    Bejar R, Stevenson KE, Caughey BA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:33763382.

    • Search Google Scholar
    • Export Citation
  • 39.

    Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013;121:260269.

    • Search Google Scholar
    • Export Citation
  • 40.

    Xie M, Lu C, Wang J. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:14721478.

  • 41.

    Jaiswal S, Fontanillas P, Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:24882498.

  • 42.

    Cargo CA, Rowbotham N, Evans PA. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015;126:23622365.

    • Search Google Scholar
    • Export Citation
  • 43.

    Kwok B, Hall JM, Witte JS. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015;126:23552361.

    • Search Google Scholar
    • Export Citation
  • 44.

    Bejar R, Stevenson K, Abdel-Wahab O. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:24962506.

  • 45.

    Papaemmanuil E, Gerstung M, Malcovati L. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:36163627.

    • Search Google Scholar
    • Export Citation
  • 46.

    Haferlach T, Nagata Y, Grossmann V. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241247.

  • 47.

    Itzykson R, Kosmider O, Renneville A. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:24282436.

    • Search Google Scholar
    • Export Citation
  • 48.

    Patnaik MM, Itzykson R, Lasho TL. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 2014;28:22062212.

    • Search Google Scholar
    • Export Citation
  • 49.

    Walter MJ, Ding L, Shen D. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:11531158.

  • 50.

    Graubert TA, Shen D, Ding L. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:5357.

  • 51.

    Thol F, Kade S, Schlarmann C. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119:35783584.

    • Search Google Scholar
    • Export Citation
  • 52.

    Makishima H, Yoshida K, Nguyen N. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013;45:942946.

  • 53.

    Patnaik MM, Lasho TL, Hodnefield JM. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569572.

    • Search Google Scholar
    • Export Citation
  • 54.

    Itzykson R, Kosmider O, Cluzeau T. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:11471152.

    • Search Google Scholar
    • Export Citation
  • 55.

    Bejar R, Lord A, Stevenson K. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014;124:27052712.

    • Search Google Scholar
    • Export Citation
  • 56.

    Sebaa A, Ades L, Baran-Marzack F. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer 2012;51:10861092.

    • Search Google Scholar
    • Export Citation
  • 57.

    Jadersten M, Saft L, Smith A. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011;29:19711979.

    • Search Google Scholar
    • Export Citation
  • 58.

    Mallo M, Del Rey M, Ibanez M. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol 2013;162:7486.

    • Search Google Scholar
    • Export Citation
  • 59.

    Jadersten M, Saft L, Pellagatti A. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009;94:17621766.

    • Search Google Scholar
    • Export Citation
  • 60.

    Mohamedali AM, Alkhatabi H, Kulasekararaj A. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood 2013;122:567570.

    • Search Google Scholar
    • Export Citation
  • 61.

    Cheson BD, Bennett JM, Kantarjian H. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:36713674.

    • Search Google Scholar
    • Export Citation
  • 62.

    Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419425.

    • Search Google Scholar
    • Export Citation
  • 63.

    Greenberg P, Baer M, Bennett J. NCCN Practice Guidelines for Myelodysplastic Syndromes, Version1, 2001. The Complete Library of NCCN Guidelines [CD-ROM],. Rockledge, PA; 2001.

    • Search Google Scholar
    • Export Citation
  • 64.

    Greenberg PL, Tuechler H, Schanz J. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012;120:24542465.

    • Search Google Scholar
    • Export Citation
  • 65.

    Mannone L, Gardin C, Quarre MC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133:513519.

    • Search Google Scholar
    • Export Citation
  • 66.

    Musto P, Lanza F, Balleari E. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204209.

    • Search Google Scholar
    • Export Citation
  • 67.

    Giraldo P, Nomdedeu B, Loscertales J. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107:28072816.

    • Search Google Scholar
    • Export Citation
  • 68.

    Stasi R, Abruzzese E, Lanzetta G. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:19211927.

    • Search Google Scholar
    • Export Citation
  • 69.

    Hellstrom-Lindberg E, Ahlgren T, Beguin Y. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:6875.

    • Search Google Scholar
    • Export Citation
  • 70.

    Jadersten M, Malcovati L, Dybedal I. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:36073613.

    • Search Google Scholar
    • Export Citation
  • 71.

    Park S, Grabar S, Kelaidi C. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574582.

    • Search Google Scholar
    • Export Citation
  • 72.

    Kelaidi C, Beyne-Rauzy O, Braun T. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013;92:621631.

    • Search Google Scholar
    • Export Citation
  • 73.

    Tehranchi R, Fadeel B, Schmidt-Mende J. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 2005;11:62916299.

    • Search Google Scholar
    • Export Citation
  • 74.

    Kelaidi C, Park S, Brechignac S. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008;32:10491053.

    • Search Google Scholar
    • Export Citation
  • 75.

    Greenberg PL, Sun Z, Miller KB. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114:23932400.

    • Search Google Scholar
    • Export Citation
  • 76.

    Phurrough S, Jacques L, Ciccanti M. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Available at: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=203&ver=12&NcaName=Erythropoiesis+Stimulating+Agents+&bc=BEAAAAAAIAAA. Accessed December 19, 2017.

    • Search Google Scholar
    • Export Citation
  • 77.

    Fenaux P, Mufti GJ, Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223232.

    • Search Google Scholar
    • Export Citation
  • 78.

    Kantarjian H, Issa JP, Rosenfeld CS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:17941803.

    • Search Google Scholar
    • Export Citation
  • 79.

    Lubbert M, Suciu S, Baila L. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:19871996.

    • Search Google Scholar
    • Export Citation
  • 80.

    Silverman LR, Demakos EP, Peterson BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Broup B. J Clin Oncol 2002;20:24292440.

    • Search Google Scholar
    • Export Citation
  • 81.

    Silverman LR, McKenzie DR, Peterson BL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:38953903.

    • Search Google Scholar
    • Export Citation
  • 82.

    Silverman LR, Fenaux P, Mufti GJ. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:26972702.

    • Search Google Scholar
    • Export Citation
  • 83.

    Lyons RM, Cosgriff TM, Modi SS. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:18501856.

    • Search Google Scholar
    • Export Citation
  • 84.

    Martin MG, Walgren RA, Procknow E. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 2009;84:560564.

    • Search Google Scholar
    • Export Citation
  • 85.

    Lubbert M, Wijermans P, Kunzmann R. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br J Haematol 2001;114:349357.

    • Search Google Scholar
    • Export Citation
  • 86.

    Wijermans P, Lubbert M, Verhoef G. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956962.

    • Search Google Scholar
    • Export Citation
  • 87.

    van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2’-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004;28:785790.

    • Search Google Scholar
    • Export Citation
  • 88.

    Saba HI, Lubbert M, Wijermans PW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood 2005;106:2515.

    • Search Google Scholar
    • Export Citation
  • 89.

    Kantarjian HM, O'Brien S, Shan J. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109:265273.

    • Search Google Scholar
    • Export Citation
  • 90.

    Kantarjian H, Oki Y, Garcia-Manero G. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:5257.

    • Search Google Scholar
    • Export Citation
  • 91.

    Damaj G, Duhamel A, Robin M. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012;30:45334540.

    • Search Google Scholar
    • Export Citation
  • 92.

    Field T, Perkins J, Huang Y. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010;45:255260.

    • Search Google Scholar
    • Export Citation
  • 93.

    Gerds AT, Gooley TA, Estey EH. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012;18:12111218.

    • Search Google Scholar
    • Export Citation
  • 94.

    Lubbert M, Bertz H, Ruter B. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009;44:585588.

    • Search Google Scholar
    • Export Citation
  • 95.

    Santini V, Almeida A, Giagounidis A. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol 2016;34:29882996.

    • Search Google Scholar
    • Export Citation
  • 96.

    Fenaux P, Giagounidis A, Selleslag D. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:37653776.

    • Search Google Scholar
    • Export Citation
  • 97.

    Deeg HJ, Jiang PY, Holmberg LA. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004;28:11771180.

    • Search Google Scholar
    • Export Citation
  • 98.

    Molldrem JJ, Caples M, Mavroudis D. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699705.

  • 99.

    Garg R, Faderl S, Garcia-Manero G. Phase II study of rabbit antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 2009;23:12971302.

    • Search Google Scholar
    • Export Citation
  • 100.

    Passweg JR, Giagounidis AA, Simcock M. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol 2011;29:303309.

    • Search Google Scholar
    • Export Citation
  • 101.

    Dunn DE, Tanawattanacharoen P, Boccuni P. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999;131:401408.

    • Search Google Scholar
    • Export Citation
  • 102.

    Saunthararajah Y, Nakamura R, Nam JM. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:15701574.

    • Search Google Scholar
    • Export Citation
  • 103.

    Sloand EM, Wu CO, Greenberg P. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:25052511.

    • Search Google Scholar
    • Export Citation
  • 104.

    Scheinberg P, Nunez O, Weinstein B. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430438.

  • 105.

    Stadler M, Germing U, Kliche KO. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460465.

    • Search Google Scholar
    • Export Citation
  • 106.

    Alsultan A, Goldenberg NA, Kaiser N. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer 2009;52:626630.

    • Search Google Scholar
    • Export Citation
  • 107.

    Macartney C, Freilich M, Odame I. Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. Pediatr Blood Cancer 2009;52:525527.

    • Search Google Scholar
    • Export Citation
  • 108.

    Jerez A, Clemente MJ, Makishima H. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 2013;122:24532459.

    • Search Google Scholar
    • Export Citation
  • 109.

    List A, Kurtin S, Roe DJ. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549557.

  • 110.

    Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006;24:25762582.

    • Search Google Scholar
    • Export Citation
  • 111.

    Giagounidis A, Mufti GJ, Mittelman M. Outcomes in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol 2014;93:429438.

    • Search Google Scholar
    • Export Citation
  • 112.

    Kuendgen A, Lauseker M, List AF. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 2013;24:10721079.

    • Search Google Scholar
    • Export Citation
  • 113.

    Raza A, Reeves JA, Feldman EJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:8693.

    • Search Google Scholar
    • Export Citation
  • 114.

    Toma A, Kosmider O, Chevret S. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 2016;30:897905.

    • Search Google Scholar
    • Export Citation
  • 115.

    Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 1986;63:477483.

    • Search Google Scholar
    • Export Citation
  • 116.

    Estey EH, Thall PF, Cortes JE. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:35753583.

    • Search Google Scholar
    • Export Citation
  • 117.

    Sonneveld P, van Dongen JJ, Hagemeijer A. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 1993;7:963969.

    • Search Google Scholar
    • Export Citation
  • 118.

    Advani R, Saba HI, Tallman MS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999;93:787795.

    • Search Google Scholar
    • Export Citation
  • 119.

    Wattel E, Solary E, Hecquet B. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Adv Exp Med Biol 1999;457:3546.

    • Search Google Scholar
    • Export Citation
  • 120.

    Greenberg PL, Lee SJ, Advani R. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:10781086.

    • Search Google Scholar
    • Export Citation
  • 121.

    Anderson JE, Appelbaum FR, Fisher LD. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677681.

    • Search Google Scholar
    • Export Citation
  • 122.

    De Witte T, Zwaan F, Hermans J. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990;74:151155.

    • Search Google Scholar
    • Export Citation
  • 123.

    Demuynck H, Verhoef GE, Zachee P. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 1996;17:745751.

    • Search Google Scholar
    • Export Citation
  • 124.

    Jurado M, Deeg HJ, Storer B. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002;8:161169.

    • Search Google Scholar
    • Export Citation
  • 125.

    Kerbauy DM, Chyou F, Gooley T. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005;11:713720.

    • Search Google Scholar
    • Export Citation
  • 126.

    Nevill TJ, Fung HC, Shepherd JD. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998;92:19101917.

    • Search Google Scholar
    • Export Citation
  • 127.

    Scott BL, Sandmaier BM, Storer B. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128135.

    • Search Google Scholar
    • Export Citation
  • 128.

    Wallen H, Gooley TA, Deeg HJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005;23:34393446.

    • Search Google Scholar
    • Export Citation
  • 129.

    Fukumoto JS, Greenberg PL. Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2005;56:179192.

  • 130.

    Revicki DA, Brandenburg NA, Muus P. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res 2013;37:259265.

    • Search Google Scholar
    • Export Citation
  • 131.

    Oliva EN, Latagliata R, Lagana C. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma 2013;54:24582465.

    • Search Google Scholar
    • Export Citation
  • 132.

    Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:6771.

    • Search Google Scholar
    • Export Citation
  • 133.

    Negrin RS, Stein R, Doherty K. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:40764081.

    • Search Google Scholar
    • Export Citation
  • 134.

    Greenberg P. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. Int J Ped HemOnc 1997;4:231238.

  • 135.

    Casadevall N, Durieux P, Dubois S. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321327.

    • Search Google Scholar
    • Export Citation
  • 136.

    Hellstrom-Lindberg E, Negrin R, Stein R. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99:344351.

    • Search Google Scholar
    • Export Citation
  • 137.

    Spiriti MA, Latagliata R, Niscola P. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005;84:167176.

    • Search Google Scholar
    • Export Citation
  • 138.

    Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:10371046.

    • Search Google Scholar
    • Export Citation
  • 139.

    Fili C, Malagola M, Follo MY. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res 2013;19:32973308.

    • Search Google Scholar
    • Export Citation
  • 140.

    Platzbecker U, Wong RS, Verma A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol 2015;2:e417426.

    • Search Google Scholar
    • Export Citation
  • 141.

    Giagounidis A, Mufti GJ, Fenaux P. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014;120:18381846.

    • Search Google Scholar
    • Export Citation
  • 142.

    Alyea EP, Kim HT, Ho V. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:18101814.

    • Search Google Scholar
    • Export Citation
  • 143.

    Cutler CS, Lee SJ, Greenberg P. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579585.

    • Search Google Scholar
    • Export Citation
  • 144.

    Alessandrino EP, Della Porta MG, Bacigalupo A. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008;112:895902.

    • Search Google Scholar
    • Export Citation
  • 145.

    Laport GG, Sandmaier BM, Storer BE. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008;14:246255.

    • Search Google Scholar
    • Export Citation
  • 146.

    McClune BL, Weisdorf DJ, Pedersen TL. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010;28:18781887.

    • Search Google Scholar
    • Export Citation
  • 147.

    Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 2009;43:597609.

  • 148.

    Oliansky DM, Antin JH, Bennett JM. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009;15:137172.

    • Search Google Scholar
    • Export Citation
  • 149.

    Deeg H, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010;116:47624770.

  • 150.

    Sorror ML, Sandmaier BM, Storer BE. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011;306:18741883.

    • Search Google Scholar
    • Export Citation
  • 151.

    Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012;119:56325639.

  • 152.

    Bokhari SW, Watson L, Nagra S. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant 2012;47:528534.

    • Search Google Scholar
    • Export Citation
  • 153.

    Koreth J, Pidala J, Perez WS. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013;31:26622670.

    • Search Google Scholar
    • Export Citation
  • 154.

    Beran M, Shen Y, Kantarjian H. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001;92:19992015.

    • Search Google Scholar
    • Export Citation
  • 155.

    Gore SD, Fenaux P, Santini V. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013;98:10671072.

    • Search Google Scholar
    • Export Citation
  • 156.

    Seymour JF, Fenaux P, Silverman LR. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218227.

    • Search Google Scholar
    • Export Citation
  • 157.

    Kornblith AB, Herndon JE II, Silverman LR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20:24412452.

    • Search Google Scholar
    • Export Citation
  • 158.

    Thomas M. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:263295.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 2947 2052 184
PDF Downloads 1204 904 89
EPUB Downloads 0 0 0